LONDON - GlaxoSmithKline (NYSE:GSK) has sold a portion of its stake in consumer health company Haleon (LON:HLN), with the transaction valued at approximately $1.27 billion. This strategic move has reduced GSK's ownership by about 3.2%, leaving the pharmaceutical giant with a 4.2% stake in Haleon.
The sale occurred at a price lower than Haleon's closing rate on the previous day, signaling GSK's intent to divest its position in the consumer health firm. Despite the lower sale price, GSK's remaining 4.2% stake signifies it still maintains a vested interest in Haleon's business trajectory.
The financial details of the transaction were not disclosed beyond the valuation, but it represents a significant step for GSK as it adjusts its investment in Haleon. Investors and market observers are keeping a close watch on how this divestiture will impact both GSK and Haleon's market performance and strategic direction moving forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.